- Meeting abstract
- Open Access
Is serum myoglobin an early marker of reperfusion in thrombolysed AMI?
Critical Care volume 1, Article number: P109 (1997)
Background and objectives
Since early reperfusion of an occluded artery proved to be the essential mechanism of the improved prognosis and mortality reduction, better prediction of successful thrombolysis had become a priority.
Our study aimed to prove that serum myoglobin determination allows better prediction of blood flow re-establishment.
As successful reperfusion causes an earlier release of biochemical markers of myocardial necrosis, we supposed that early and repeated dosage of serum myoglobin would permit a better prediction of recanalisation.
We studied the serum myoglobin levels in 47 patients presenting an AMI: 37 intravenous patients were treated by thrombolysis (rTPA); five by emergency TGA; and four patients presented a contraindication to either one methods. Thirty-two from 37 patients were reperfused during the first 90 min, five were not.
A fourfold increase in the first 90 min is a good predicting factor of reperfusion (78% sensibility, 89% positive predicting value, 40% specificity, 25% negative predicting value). The low results for specificity and negative predicting value are probably due to the small number of non-reperfused patients.
Determination of serum myoglobin levels during the first 90 min of an AMI treated by intravenous thrombolysis may accurately identify successful reperfusion if used in association with the other reperfusion predicting factors (resolution of the ST-segment elevation, pain resolution, arrhythmias), but larger series are necessary before generalisation of this technique. Thus, lower cost and rapid assay device make this method interesting for early assessment of myocardial reperfusion.
About this article
Cite this article
Halchini, C., Hanssen, M., Gottwalles, Y. et al. Is serum myoglobin an early marker of reperfusion in thrombolysed AMI?. Crit Care 1, P109 (1997). https://0-doi-org.brum.beds.ac.uk/10.1186/cc3856
- Good Prediction
- Mortality Reduction
- Fourfold Increase
- Myocardial Necrosis
- Early Assessment